Lack of Correlation Between Clinical Characteristics and Serum Soluble Fas Ligand Levels in Patients with Multiple Myeloma

Yoshinobu Kanda Department of Hematology, International Medical Center of Japan, JapanCorrespondence[email protected]

Chiaki Arai Department of Hematology, International Medical Center of Japan, Japan

Akichizuka Department of Hematology, International Medical Center of Japan, Japan

Rie Yamamoto Department of Hematology, International Medical Center of Japan, Japan

Tamae Hamaki Department of Hematology, International Medical Center of Japan, Japan

Miyuki Suguro Department of Hematology, International Medical Center of Japan, Japan

Tomohiro Matsuyama Department of Hematology, International Medical Center of Japan, Japan

Naoki Takezako Department of Hematology, International Medical Center of Japan, Japan

Akiyoshi Miwa Department of Hematology, International Medical Center of Japan, Japan

Junko Tohma Biosciences Laboratory, Research Center, Mochida Pharmaceutical Co, Japan

Kamon Shirakawa Biosciences Laboratory, Research Center, Mochida Pharmaceutical Co, Japan

Takehiro Yatomi Biosciences Laboratory, Research Center, Mochida Pharmaceutical Co, Japan

Norio Nakamura Biosciences Laboratory, Research Center, Mochida Pharmaceutical Co, Japan

Hisamaru Hirai Department of Cell Therapy & Transplantation Medicine, Faculty of Medicine, University of Tokyo, Japan

Atsushi Togawa Department of Hematology, International Medical Center of Japan, Japan

show all

Abstract

Multiple myeloma is characterized by the accumulation of malignant plasma cells in the bone marrow and rarely cured by chemotherapy. Villunger et al. showed that the neoplastic plasma cells express Fas ligand (FasL), which transmits a signal of apoptosis upon ligation to Fas, and suggested that the FasL suppresses the T-cells activated against malignant cells, resulting in escape from tumour immunity. We examined serum soluble FasL (sFasL) levels in 35 multiple myeloma patients to evaluate the correlation between sFasL levels and clinical characteristics. The serum sFasL levels were not affected by the disease status, serum monoclonal protein levels, or other prognostic factors. We could not determine whether the expression of FasL is involved in the poor clinical course of the disease.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Lack of Correlation Between Clinical Characteristics and Serum Soluble Fas Ligand Levels in Patients with Multiple Myeloma

Information for

Open access

Opportunities

Help and information

Lack of Correlation Between Clinical Characteristics and Serum Soluble Fas Ligand Levels in Patients with Multiple Myeloma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature